MSC2530818

A Cdk8 inhibitor

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥1525.00

1220.00

- +
10mg

￥2437.00

1950.00

- +
25mg

￥5175.00

4140.00

- +
50mg

￥8412.00

6730.00

- +
100mg

￥16187.00

12950.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

MSC2530818 is an orally bioavailable cyclin-dependent kinase 8 (Cdk8) inhibitor (IC₅₀ = 2.6 nM).¹ It is selective for Cdk8 over a panel of 264 kinases at 1 ?M but does inhibit glycogen synthase kinase 3α (GSK3α; IC₅₀ = 691 nM). MSC2530818 inhibits STAT1 phosphorylation in SW620 colorectal cancer cells with an IC₅₀ value of 8 nM. It also inhibits Wnt-dependent transcription in LS 174T, COLO 205, and PA-1 cancer cells (IC₅₀s = 32, 9, and 52 nM, respectively, in luciferase reporter assays). MSC2530818 (50 and 100 mg/kg) reduces tumor growth in a SW620 mouse xenograft model.

1.Czodrowski, P., Mallinger, A., Wienke, D., et al.Structure-based optimization of potent, selective, and orally bioavailable CDK8 inhibitors discovered by high-throughput screeningJ. Med. Chem.59(20)9337-9349(2016)

Protocol

Animal experiment:

Mice: MSC2530818 is then assessed in an established SW620 human colorectal cancer xenograft model in female NCr athymic mice. Tumor-bearing mice are treated orally with MSC2530818 (50 mg/kg bid or 100 mg/kg qd) for 16 days. Tumor weights are measured and body weights are monitored[1].

参考文献:

[1]. Czodrowski P, et al. Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening. J Med Chem. 2016 Oct 27;59(20):9337-9349.